Compound guide · Tier D
MOTS-c
Genuinely interesting biology from real academic research, sold years ahead of any human evidence that it does anything in a person.
The short answer
MOTS-c is a legitimate scientific discovery being sold as if it were a finished product. The underlying finding, that the mitochondrial genome encodes short peptides with signalling roles, is real and was published in serious journals. The animal work on metabolic regulation, insulin sensitivity and exercise capacity is genuinely suggestive. What does not exist is a controlled human trial showing any of that happens in people. Buying MOTS-c is buying a hypothesis at a stage of development where the pharmaceutical industry would still be doing toxicology. That may turn out well and there is currently no way for anyone, including us, to tell you that it will.
At a glance
| Class | Mitochondrial derived peptide, encoded in mitochondrial DNA |
| Developer | No developer. Identified in academic research at the University of Southern California. |
| Sold as | None. Sold only as research material. |
| Regulatory status | Not approved by any regulator, anywhere, for any indication. There is no marketing authorisation for MOTS-c from the FDA, the EMA, the MHRA, the TGA or SAHPRA, and no registration trial has been completed. |
| Compounding status | There is no approved MOTS-c product to compound an equivalent of, and no regulator has evaluated it. |
| Anti-doping | Not specifically named on the prohibited list. Given its metabolic and performance framing, anyone in tested sport should check the list as published each year rather than assume. |
| Our evidence tier | Tier D. Preclinical evidence only |
What it is
MOTS-c is a 16 amino acid peptide encoded within the mitochondrial 12S rRNA gene, one of a small group of mitochondrial derived peptides identified over the past two decades. It is described as acting on metabolic homeostasis, including AMPK signalling and insulin sensitivity, and levels appear to change with exercise and with age. That is an interesting biological observation. It is a long way from a therapeutic claim.
Who it is for, and who actually takes it
Nobody, in the regulatory sense. There is no approved population and no completed registration programme. The research population is cells and rodents.
It is bought for metabolic health, insulin sensitivity, endurance and longevity, by people extrapolating directly from mouse studies to themselves. The framing around exercise mimetics has made it particularly attractive to the endurance and longevity communities.
What the research shows
Every controlled MOTS-c result is from cells or rodents. Charting animal data beside our human trial charts would imply a parity of evidence that does not exist, so we state the absence instead.
Dosing
We publish no dosing for MOTS-c and there is none to publish. No regulator has approved a dose and no controlled human trial has established one. Figures circulating on vendor pages and forums derive from rodent studies, and scaling a mouse dose to a person is not a calculation anyone should be doing at home from a table on the internet. We publish no reconstitution guidance.
What happens when you come off it
No discontinuation data exists because no controlled human administration data exists. Anything you read describing what happens when you stop is anecdote.
What it is being studied for
| Area | Stage of evidence |
|---|---|
| Insulin sensitivity and metabolic regulation | Preclinical, cell and rodent models |
| Exercise capacity and endurance | Preclinical, rodent models |
| Age related metabolic decline | Preclinical, plus observational human association studies |
| Obesity | Preclinical |
| Any clinical outcome in humans | No controlled trial |
The observational human work measures circulating MOTS-c levels and correlates them with fitness or age. That is an association in the opposite direction to the one buyers assume: it shows the peptide tracks with a state, not that administering it produces that state.
Common myths
MOTS-c is an exercise mimetic, so it gives you the benefits of exercise.
Exercise mimetic is a description of a research hypothesis, not of a demonstrated effect in people. The claim rests on rodent work, and no controlled human trial has shown that administering MOTS-c reproduces any benefit of exercise.
It is natural because your body already makes it.
Your body makes it in specific tissues at specific concentrations under specific regulation. Injecting a synthetic version at a dose someone guessed from a mouse study is not the same thing, and endogenous origin has never established the safety of exogenous administration.
Low MOTS-c is associated with ageing, so raising it should help.
That inference is the single most common error in longevity marketing. A marker that changes with age is not necessarily a cause of ageing, and correcting a marker is not the same as correcting a process.
There is human research on MOTS-c.
There are human observational studies measuring natural levels. There is no controlled trial of administering it. Those are entirely different kinds of evidence and vendor pages routinely blur them.
Verifying a purchase
MOTS-c is a 16 amino acid peptide, which is short enough to synthesise cheaply and to substitute easily. Identity by mass spectrometry is the check that matters, tied to the batch code on your vial. The published lot report for this vendor is one of the better ones in the catalogue on content, at 40.37 mg against a 40 mg label, which is 100.9%.
The general method is set out in our guide to reading a certificate of analysis, which covers the eleven checks that apply to any compound. The points above are the ones specific to MOTS-c.
Caveats and safety
There is no human safety database for MOTS-c at all. No toxicology programme has been published, no dose ranging study has been conducted in people, and no adverse event surveillance exists. That is not a claim of danger, it is an absence of information, and it should be read as the open question it is rather than as reassurance.
Where to get it
Where to get it
CertaPeptides Romania, EU. Volume discounts at 3+, 5+ and 10+ units.
| Vial | Price |
|---|---|
| 10 mg | €41.99 |
| 40 mg | €103.49 |
Stated purity. ≥98% stated batch specification. Published lot report #204783 returned 99.27% on a 40 mg vial, with 40.37 mg measured against a 40 mg label, which is 100.9% of stated content.
Documentation. Selected lots independently tested by Janoshik Analytical (Czech Republic), HPLC plus mass spectrometry, reports searchable on the Janoshik public portal and at certapeptides.com/verify.
MOTS-c is sold as laboratory research material. The vendor states it is not for human consumption and that it is not approved by the FDA, the EMA or any other regulator for use in humans or animals. Read the evidence tier at the top of this page before the price.
View MOTS-c at CertaPeptidesAffiliate link. We earn a commission if you buy, at no extra cost to you. It does not change a word of the assessment above. Every product we have priced, in one list.
Sources
- MOTS-c literature, PubMed
- Registered MOTS-c trials, ClinicalTrials.gov
- Drugs@FDA, for absence of approval
- WADA Prohibited List
Related compounds
Disclosure. PeptoPurity is an affiliate of CertaPeptides and earns a commission on qualifying purchases made through the vendor link on this page, at no additional cost to you. That relationship does not set the evidence tier, alter the verdict, or change a word of the assessment. Our Tier C and Tier D pages carry the same links as our Tier A pages, with the same conclusions we would publish if we earned nothing. Where the registered, prescribed route is the better option, we say so on the page that would otherwise pay us.
Scope. This is an evidence review, not medical advice. Where an approved label schedule is reproduced it is a record of what a regulator has published about a licensed medicine, not a recommendation and not a schedule for anyone to follow unsupervised. For unapproved compounds we report only the doses used in published studies, attributed to those studies, and we publish no protocols and no reconstitution guidance for any compound. Regulatory status differs between countries and changes over time. Material sold for laboratory research is not approved for human use. Decisions about treatment belong with a qualified prescriber.